Glutaminase

Newfound Mechanism Suggests Drug Combination Could Starve Pancreatic Cancer

Retrieved on: 
Monday, October 9, 2023
University of British Columbia, Doctor of Philosophy, Division, New York University Grossman School of Medicine, DON, Kimmelman, Glutaminase, MD, PDAC, Lustgarten Foundation for Pancreatic Cancer Research, Toxicity, Biochemistry, National Cancer Institute, Lung cancer, University, Survival, NYU Langone Health, Nature Cancer, Cancer, Therapy, Glutamine, Environment, Growth, Oxygen, ERK, Mouse, NYU, Pancreatic cancer, Neoplasm, Molecular biology, Enzyme, Radiation therapy, Medical imaging, Pharmaceutical industry

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

Key Points: 
  • NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
  • Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch.
  • DON was designed to starve cancer cells by mimicking glutamine, which unlike glutaminase blockers, broadly inhibits all metabolic pathways that use glutamine.
  • In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer.

AI Tools are Enhancing Inclusivity and Reducing Bias in Hiring Processes

Retrieved on: 
Tuesday, May 9, 2023
PDN, Natural language processing, Analytics, Communication, Partnership, Probability, Original equipment manufacturer, ChatGPT, Street, Intelligence, Holding, Uniloc USA, Inc. v. Microsoft Corp., OpenAI, SOC, Language, CV22, CRUK, Spondias dulcis, Acquisition, Machine learning, Innodata, Drug discovery, Artificial intelligence, Diagnosis, Growth, Neoplasm, AI, BBAI, ADAS, Transport, Fraud, Bias, News, NYSE, Financial News, Total, Automation, Cryptocurrency, Sales, Online shopping, Glutaminase

NEW YORK, May 9, 2023 /PRNewswire/ -- Artificial intelligence (AI) has rapidly evolved over the last decade. With advancements in machine learning, natural language processing, and computer vision, AI is revolutionizing the way we interact with technology and each other. One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI. With its advanced natural language processing capabilities, ChatGPT can understand human language and generate human-like responses, making it an ideal tool for customer service, virtual assistants, and chatbots. The impact of AI is already being felt across various industries, from healthcare and finance to transportation and manufacturing. For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans. In finance, AI is being used to detect fraud, predict market trends, and optimize investment strategies. Professional Diversity Network, Inc. (NASDAQ: IPDN), Innodata Inc. (NASDAQ: INOD), Ambarella, Inc. (NASDAQ: AMBA), BigBear.ai Holdings, Inc. (NYSE: BBAI), Predictive Oncology Inc. (NASDAQ: POAI)

Key Points: 
  • One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI.
  • For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans.
  • AI tools, on the other hand, can analyze large amounts of data without being influenced by personal biases.
  • Moreover, fraud detection AI tools can help companies identify and eliminate fake resumes and fraudulent job applications.

AI Tools are Enhancing Inclusivity and Reducing Bias in Hiring Processes

Retrieved on: 
Tuesday, May 9, 2023
PDN, Natural language processing, Analytics, Communication, Partnership, Probability, Original equipment manufacturer, ChatGPT, Street, Intelligence, Holding, Uniloc USA, Inc. v. Microsoft Corp., OpenAI, SOC, Language, CV22, CRUK, Spondias dulcis, Acquisition, Machine learning, Innodata, Drug discovery, Artificial intelligence, Diagnosis, Growth, Neoplasm, AI, BBAI, ADAS, Transport, Fraud, Bias, News, NYSE, Financial News, Total, Automation, Cryptocurrency, Sales, Online shopping, Glutaminase

NEW YORK, May 9, 2023 /PRNewswire/ -- Artificial intelligence (AI) has rapidly evolved over the last decade. With advancements in machine learning, natural language processing, and computer vision, AI is revolutionizing the way we interact with technology and each other. One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI. With its advanced natural language processing capabilities, ChatGPT can understand human language and generate human-like responses, making it an ideal tool for customer service, virtual assistants, and chatbots. The impact of AI is already being felt across various industries, from healthcare and finance to transportation and manufacturing. For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans. In finance, AI is being used to detect fraud, predict market trends, and optimize investment strategies. Professional Diversity Network, Inc. (NASDAQ: IPDN), Innodata Inc. (NASDAQ: INOD), Ambarella, Inc. (NASDAQ: AMBA), BigBear.ai Holdings, Inc. (NYSE: BBAI), Predictive Oncology Inc. (NASDAQ: POAI)

Key Points: 
  • One recent development in the field of AI is the launch of ChatGPT, a language model developed by OpenAI.
  • For example, in the healthcare industry, AI is being used to analyze medical images, assist in diagnosis, and develop personalized treatment plans.
  • AI tools, on the other hand, can analyze large amounts of data without being influenced by personal biases.
  • Moreover, fraud detection AI tools can help companies identify and eliminate fake resumes and fraudulent job applications.

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Retrieved on: 
Friday, April 14, 2023
Glutaminase, AACR, Kidney cancer, Messenger, NCNA, Patient, GAC, Growth, Hypoxia, American Association for Cancer Research, PD-L1, Medical imaging

ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters to be presented at the American Association of Cancer Research (AACR) Annual Meeting being held from April 14-19, 2023.

Key Points: 
  • ORLANDO, Fla., April 14, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters to be presented at the American Association of Cancer Research (AACR) Annual Meeting being held from April 14-19, 2023.
  • These data indicate that NUC-7738 has the potential to act as an immune sensitizer and as an effective combination partner for PD-L1 pathway inhibitors.
  • NUC-7738 reduced the expression of GAC in renal and pancreatic cancer cell lines in both hypoxic and normoxic conditions.
  • We are currently investigating NUC-7738 in combination with pembrolizumab in the Phase 2 part of the NuTide:701 study and look forward to sharing data from this study in 2023.”

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs

Retrieved on: 
Friday, March 17, 2023
Oncology, Partnership, Probability, Cancer research, Cancer, Cancer Research UK, Intelligence, Research, CRUK, Patient, Drug discovery, Neoplasm, Pharmaceutical industry, Glutaminase

EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.

Key Points: 
  • EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.
  • “Our collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery that could lead to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with their global network,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology.
  • We look forward to applying Predictive Oncology’s expertise, enabling technology and dedication to progress exciting cancer therapeutics,” explained Tony Hickson, Chief Business Officer for Cancer Research UK and Cancer Research Horizons.
  • Cancer Research Horizons realizes cancer patient benefit from not-for-profit research and works closely with leading cancer scientists, institutes and companies to protect, develop and commercialize oncology-related discoveries.

Angel Yeast Invests in New Enzyme Project Capable of 5,000 Tons Annual Production Output

Retrieved on: 
Wednesday, December 22, 2021
RMB, Technology, China Biologic Products, Biofuel, Efficiency, General manager, Lactase, Enzyme, Glutaminase, Biotechnology, Proteolysis, R, Multimedia, Fine chemical, Beer

Once complete, the project will have an annual enzyme production output of 5,000 tons and will significantly enhance the company's competitive advantage in the enzyme preparations and biotechnology industry.

Key Points: 
  • Once complete, the project will have an annual enzyme production output of 5,000 tons and will significantly enhance the company's competitive advantage in the enzyme preparations and biotechnology industry.
  • Angel Enzyme Preparation's new green manufacturing project will cover 80 hectares and has a planned total investment of RMB 340 million.
  • Angel Enzyme Preparation was established in 2021 as a wholly-owned subsidiary of Angel Yeast and is registered in Yichang, Hubei Province.
  • Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives.

Angel Yeast Invests in New Enzyme Project Capable of 5,000 Tons Annual Production Output

Retrieved on: 
Wednesday, December 22, 2021
RMB, Technology, China Biologic Products, Biofuel, Efficiency, General manager, Lactase, Enzyme, Glutaminase, Biotechnology, Proteolysis, R, Fine chemical, Beer

Once complete, the project will have an annual enzyme production output of 5,000 tons and will significantly enhance the company's competitive advantage in the enzyme preparations and biotechnology industry.

Key Points: 
  • Once complete, the project will have an annual enzyme production output of 5,000 tons and will significantly enhance the company's competitive advantage in the enzyme preparations and biotechnology industry.
  • Angel Enzyme Preparation's new green manufacturing project will cover 80 hectares and has a planned total investment of RMB 340 million.
  • Angel Enzyme Preparation was established in 2021 as a wholly-owned subsidiary of Angel Yeast and is registered in Yichang, Hubei Province.
  • Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives.

Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019

Retrieved on: 
Friday, December 6, 2019
Glutamate, Chemical compounds, Organic compounds, Lactams, Nucleosides, Triazines, Health, Azacitidine, Glutaminase, Glutamine

Date: Monday, December 9 at 7:30 a.m. Eastern Time

Key Points: 
  • Date: Monday, December 9 at 7:30 a.m. Eastern Time
    Telaglenastat is an investigational first-in-class glutaminase inhibitor specifically designed to block glutamine consumption in tumor cells.
  • Additional meeting information and accepted abstracts can be found at the ASH website www.hematology.org.
  • This investigator-sponsored trial is a single arm Phase 1b/2 trial of telaglenastat in combination with azacitidine for intermediate and high-risk MDS.
  • The primary outcome was to confirm the safety and recommended dose of telaglenastat in combination with azacitidine.

Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

Retrieved on: 
Thursday, September 26, 2019
European Society for Medical Oncology, Oncology, Arginase, Glutaminase

ET) to review data from the Calithera clinical program presented at the European Society for Medical Oncology (ESMO) Congress 2019.

Key Points: 
  • ET) to review data from the Calithera clinical program presented at the European Society for Medical Oncology (ESMO) Congress 2019.
  • Calithera management will review data from the ENTRATA study evaluating the glutaminase inhibitor telaglenastat and data presented on INCB001158, an oral arginase inhibitor.
  • To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at www.calithera.com.
  • The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price.

Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

Retrieved on: 
Tuesday, September 3, 2019
Glutamate, Glutaminase, Glutamine

The oral presentation will be led by Chung-Han Lee of the Memorial Sloan Kettering Cancer Center, New York, NY.

Key Points: 
  • The oral presentation will be led by Chung-Han Lee of the Memorial Sloan Kettering Cancer Center, New York, NY.
  • Telaglenastat is an investigational first-in-class, novel glutaminase inhibitor specifically designed to block glutamine consumption in tumor cells.
  • The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
  • The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price.